Acute Intermittent Porphyria

Acute Intermittent Porphyria is a rare genetic disorder that affects the body's ability to produce heme, an important component of red blood cells. It primarily impacts the nervous system, causing episodes of severe abdominal pain, muscle weakness, and neurological symptoms such as confusion or seizures. These attacks can be triggered by certain medications, stress, or hormonal changes. The condition involves a buildup of toxic substances in the body that interfere with normal nerve function. People with this disorder may experience recurring episodes that can be life-threatening if not recognized and managed properly. The symptoms often come and go, making diagnosis challenging. Understanding the role of heme synthesis is key to grasping how this disease affects health.

Acute Intermittent Porphyria (AIP) is an autosomal dominant disorder caused by a deficiency of the enzyme porphobilinogen deaminase (also known as hydroxymethylbilane synthase), which is involved in the heme biosynthesis pathway. This enzymatic defect leads to accumulation of porphyrin precursors such as aminolevulinic acid (ALA) and porphobilinogen (PBG), which are neurotoxic. The disease manifests with acute neurovisceral attacks characterized by severe abdominal pain, peripheral neuropathy, and psychiatric symptoms. Attacks are often precipitated by factors that induce hepatic cytochrome P450 enzymes, including certain drugs, alcohol, fasting, and hormonal changes. The clinical significance lies in the potential for life-threatening complications such as respiratory paralysis and seizures. Diagnosis requires a high index of suspicion due to the nonspecific nature of symptoms and the episodic course. Genetic mutations in the HMBS gene underlie the enzymatic deficiency.